A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.

被引：0
|
作者：
Ciombor, Kristen Keon
Zemla, Tyler J.
Hubbard, Joleen M.
Jia, Jingquan
Gbolahan, Olumide B.
Sousa, Andrea
Wilson, Luke
Waechter, Blake
Ou, Fang-Shu
Nixon, Andrew B.
Bekaii-Saab, Tanios S.
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Mayo Clin, Alliance Stat & Data Management Ctr, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Emory Univ, Sch Med, Atlanta, GA USA
[6] Mayo Clin, Canc Ctr Scottsdale, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
139
引用
收藏
页码：139 / 139
页数：1
相关论文
共 50 条
  • [21] Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer
    Segal, Neil H.
    Cercek, Andrea
    Ku, Geoffrey
    Wu, Abraham J.
    Rimner, Andreas
    Khalil, Danny N.
    Reidy-Lagunes, Diane
    Cuaron, John
    Yang, T. Jonathan
    Weiser, Martin R.
    Romesser, Paul B.
    Stadler, Zsofia K.
    Varghese, Anna M.
    Ganesh, Karuna
    Yaeger, Rona
    Connell, Louise C.
    Faleck, David
    Abou-Alfa, Ghassan K.
    Mcauliffe, Kathleen C.
    Vaiskauskas, Pamela
    Solter, Mark L.
    Ogle, Martinique
    Adamow, Matthew J.
    Holland, Aliya
    Vedantam, Pallavi
    Wong, Phillip
    Merghoub, Taha
    Vakiani, Efsevia
    Hollmann, Travis J.
    Juluru, Krishna
    Chou, Joanne F.
    Capanu, Marinela
    Erinjeri, Joseph
    Solomon, Stephen
    Yamada, Yoshiya
    Kemeny, Nancy
    Crane, Christopher H.
    Saltz, Leonard B.
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2200 - 2208
  • [22] Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study).
    Shi, Guoming
    Huang, Xiaoyong
    Wen, Tianfu
    Song, Tianqiang
    Kuang, Ming
    Mou, Haibo
    Bao, Lequn
    Zhao, Hai-Tao
    Zhao, Hong
    Feng, Xielin
    Zhang, Bixiang
    Peng, Tao
    Zhang, Yubao
    Li, Xiangcheng
    Yu, Hongsheng
    Cao, Yu
    Luo, Yang
    Chen, Mingxia
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16183 - E16183
  • [23] Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347
    Iafrate, Anthony J.
    Borger, Darrell R.
    Vivancos, Ana
    Voss, Martin
    Cleary, James
    Meric-Bernstam, Funda
    Tabernero, Josep
    Flaherty, Keith
    Ishii, Nobuya
    Brichory, Franck
    Tanaka, Hiroaki
    Pokorska-Bocci, Anna
    Baselga, Jose
    Nuciforo, Paolo
    CANCER RESEARCH, 2019, 79 (13)
  • [24] Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
    Shi, Guo-Ming
    Huang, Xiao-Yong
    Wen, Tian-Fu
    Song, Tian-Qiang
    Kuang, Ming
    Mou, Hai-Bo
    Bao, Le-Qun
    Zhao, Hai-Tao
    Zhao, Hong
    Feng, Xie-Lin
    Zhang, Bi-Xiang
    Peng, Tao
    Zhang, Yu-Bao
    Li, Xiang-Cheng
    Yu, Hong-Sheng
    Cao, Yu
    Liu, Lian-Xin
    Zhang, Ti
    Wang, Wei-Lin
    Ran, Jiang-Hua
    Liu, Ying-Bin
    Gong, Wei
    Chen, Ming-Xia
    Cao, Lian
    Luo, Yang
    Wang, Yan
    Zhou, Hui
    Yang, Guo-Huan
    Fan, Jia
    Zhou, Jian
    CANCER MEDICINE, 2023, 12 (04): : 4137 - 4146
  • [25] Bevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): A single-arm, phase II study
    Makiyama, A.
    Oki, E.
    Miyamoto, Y.
    Kotaka, M.
    Kawanaka, H.
    Miwa, K.
    Kabashima, A.
    Noguchi, T.
    Yuge, K.
    Kashiwada, T.
    Shimokawa, M.
    Saeki, H.
    Akagi, Y.
    Baba, H.
    Mori, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer harboring FGF/FGFR gene aberrations.
    Guo, Ye
    Li, Qun
    Tang, Wenbo
    Lin, Fengjuan
    Xue, Junli
    Xue, Liqiong
    Ge, Xiaoxiao
    Zhao, Wei
    Zhou, Wei
    Zhao, Renbin
    Zhang, Bin
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] A phase Ib study of alofanib, an allosteric FGFR2 inhibitor, in patients with advanced or metastatic gastric cancer
    Statsenko, Galina
    Fedyanin, Mikhail
    Moiseyenko, Vladimir
    Vladimirova, Liubov Yu
    Tsimafeyeu, Ilya
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC)
    Becerra, C.
    Salazar, R.
    Garcia-Carbonero, R.
    Thomas, A. L.
    Vazquez-Mazon, F.
    Cassidy, J.
    Maughan, T.
    Gallen, M.
    Iveson, T.
    Hixon, M.
    Gualberto, A.
    Yin, D.
    Bergsland, E. K.
    Li, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] FIGHT-207: Phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations
    Feliz, Luis
    Asatiani, Ekaterine
    Lihou, Christine
    Zhen, Huiling
    Silverman, Ian
    Ahnert, Jordi Rodon
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [30] A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
    Voss, Martin H.
    Hierro, Cinta
    Heist, Rebecca S.
    Cleary, James M.
    Meric-Bernstam, Funda
    Tabernero, Josep
    Janku, Filip
    Gandhi, Leena
    Iafrate, A. John
    Borger, Darrell R.
    Ishii, Nobuya
    Hu, Youyou
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Chessex, Anne Vaslin
    Zanna, Claudio
    Flaherty, Keith T.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2699 - 2707
12345